title: Urokinase-type plasminogen activator: a new target for male contraception?
abstract: Urokinase-type plasminogen activator (uPA) is closely related to male reproduction. With the aim of investigating the possibility for uPA as a potential contraceptive target, in the present work, Kunming male mice were immunized by human uPA subcutaneous injection at three separate doses for 3 times. Then the potency of the anti-human uPA antibody in serum was analyzed, and mouse fertility was evaluated. Serum antibody titers for human uPA in immunized groups all reached 1:10,240 or higher levels by enzyme linked immunosorbent assay, and mating experiments revealed that pregnancy rates and the mean number of embryos implanted after mating declined obviously (P < 0.05) when compared with control groups. However, the mating capacity and reproductive organ weights had no obvious change, and histological analysis of the testes and epididymides also showed normal morphology for immunized male mice. Sperm function tests suggested that the sperm concentration, sperm viability, sperm motility, and in vitro fertilization rate for the cauda epididymis sperm in uPA-immunized groups were lower than those in the controls (P < 0.05). Together, these observations indicated that subcutaneous injection human uPA to the male mice could effectively reduce their fertility, and uPA could become a new target for immunocontraception in male contraceptive development.
authors.forename: Ying
authors.initials: Y
authors.lastname: Qin
authors.forename: Yan
authors.initials: Y
authors.lastname: Han
authors.forename: Cheng-Liang
authors.initials: CL
authors.lastname: Xiong
authors.forename: Hong-Gang
authors.initials: HG
authors.lastname: Li
authors.forename: Lian
authors.initials: L
authors.lastname: Hu
authors.affiliation: Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D003267:Contraception / Q000379:methods*; D003269:Contraception, Immunologic; D003272:Contraceptive Agents, Male / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D004822:Epididymis / Q000187:drug effects / Q000473:pathology; D005260:Female; D005298:Fertility / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D023421:Models, Animal; D011247:Pregnancy; D018873:Pregnancy Rate; D013081:Sperm Motility / Q000187:drug effects; D013737:Testis / Q000187:drug effects / Q000473:pathology; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000276:immunology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D003272:Contraceptive Agents, Male; D014568:Urokinase-Type Plasminogen Activator